Analysis of Functional Responses at G Protein-Coupled Receptors: Estimation of Relative Affinity Constants for the Inactive Receptor State

Frederick J. Ehler, Michael T. Griffin, and Hinako Suga

Department of Pharmacology, School of Medicine, University of California, Irvine, California (F.J.E., H.S.); and Crean School of Health and Life Sciences, Schmid College of Science, Chapman University, Orange, California (M.T.G.)

Received January 11, 2011; accepted May 13, 2011

ABSTRACT

We describe a modification of receptor theory that enables the estimation of relative affinity constants for the inactive state of a G protein-coupled receptor. Our approach includes the traditional parameters of observed affinity ($K_{obs}$) and efficacy (fraction of ligand-receptor complex in the active state, $e$) and introduces the concept of the fraction of the ligand-receptor complex in the inactive state (intrinsic inactivity, $i$). The relationship between receptor activation and the ligand concentration is known as the stimulus, and the operational model expresses the response as a logistic function of the stimulus. The latter function includes $K_{obs}$ and the parameter $\tau$, which is proportional to $e$. We introduce the parameter $\tau_i$, which is proportional to $i$. We have previously shown that the product, $K_{obs}\tau$, of one agonist, expressed relative to that of another (intrinsic relative activity, $RA_i$), is a relative measure of the affinity constant for the active state of the receptor. In this report, we show that the product, $K_{obs}\tau_i$, of one agonist, expressed relative to that of another (intrinsic relative inactivity, $RI_i$), is a relative measure of the affinity constant for the inactive state of the receptor. We use computer simulation techniques to verify our analysis and apply our method to the analysis of published data on agonist activity at the M3 muscarinic receptor. Our method should have widespread application in the analysis of agonist bias in drug discovery programs and in the estimation of a more fundamental relative measure of efficacy ($RA_i/RI_i$).

Introduction

An abundance of evidence indicates that receptors evolved to act as molecular switches that undergo a conformational change into an active state when occupied by an endogenous agonist. Some of the strongest evidence for this view comes from the results of single-channel recordings at ligand-gated ion channels, which show an abrupt quantal increase in conductance upon binding of agonist with no evidence of gradual conductance changes (Colquhoun and Sakmann, 1985). At G protein-coupled receptors, the active state of the receptor presumably interacts with a conformation of the heterotrimeric G protein that has the guanine nucleotide-binding pocket on the ras domain of Gα opened up for rapid GDP-GTP exchange (Oldham and Hamm, 2008).

The existence of quantal receptor states is not inconsistent with an agonist having a continuum of observed affinities for a G protein-coupled receptor, depending upon the concentration of G protein in the plasma membrane, the type of G protein with which the receptor interacts, and the concentration of guanine nucleotide. These factors can change the observed affinity of the agonist-receptor complex over a broad interval bounded on the high and low ends by the microscopic affinity constants of the agonist for the active and inactive states of the receptor, respectively (Ehler, 2008). Thus, two states of the receptor can give rise to a continuum of observed affinities and efficacies. There may also be multiple active receptor states that exhibit differential selectivity for signaling proteins (i.e., G proteins or G protein-coupled receptor kinases), giving rise to biased agonism (Kenakin, 2011).

Although the estimation of observed affinity and relative efficacy provides an accurate estimate of how an agonist interacts with the receptor population, these macroscopic constants can vary for the same agonist-receptor complex as just described. However, the affinity constants of the agonist for the ground ($K_a$) and active ($K_p$) states of the receptor are invariant and represent a more fundamental estimate of the agonist-receptor interaction because a change in the equilibrium between these states gives rise to variation in observed

ABBREVIATIONS: McN-A-343, 4-((m-chlorophenyl-carbamoiloxyl)-2-butynyltrimethylammonium; RSS, residual sum of squares; GTPγS, guanosine 5’-O-(3-thiotriphosphate; CHO, Chinese hamster ovary.
affinity and efficacy and not a change in the affinity of the states themselves. We have previously described how to estimate the product of observed affinity and efficacy of an agonist through analysis of the concentration-response curve (Ehlert et al., 1999; Ehlert, 2008) and have recently shown that this estimate is proportional to the microscopic affinity constant of the active state of the receptor (Tran et al., 2009).

Given the inherent symmetry of ligand-receptor interactions, we reasoned that if the product of observed affinity ($K_{obs}$) and the fraction of the agonist-receptor complex in the active state (i.e., efficacy) is proportional to $K_{sp}$, then it seems likely that the product of observed affinity and the fraction of the agonist-receptor complex in the inactive state ($1 - effi$) should be proportional to the microscopic affinity constant of the agonist for the inactive state ($K_{i}$). In the present report, we present analytical proof and computer simulation analysis showing that this postulate is correct and analyze published agonist concentration-response curves from the literature to illustrate our method for determining a relative estimate of the affinity constant of the agonist for the ground state of the receptor. We also show how to estimate the affinity constant of the agonist for the inactive state of the receptor in units of inverse molarity ($M^{-1}$) from functional data.

**Materials and Methods**

**Simulation of Agonist Concentration-Response Curves.** We generated theoretical agonist concentration-response curves and analyzed them using the method describe under Results to determine whether it was possible to estimate the relative values of the agonist affinity constants for active and inactive states of the receptor that were used to generate the data in the first place.

Our approach for the simulations is based on two assumptions: 1) activation of a G protein-coupled receptor by an agonist is equivalent to the fraction of the agonist-receptor complex in the active state associated with the G protein-guanine nucleotide complex ($DR_{a}GX$) (Ehlert and Rathbun, 1990; Ehlert, 2000) and 2) the operational model accurately describes the relationship between receptor activation and the measured response (Black and Leff, 1983). Thus, we used the following equation to generate agonist concentration-response curves:

$$Y = \frac{[DR_{a}GX]^n}{[DR_{a}GX]^n + K_{R}}$$  \hspace{1cm} (1)

In this equation, $m$ represents the transducer slope factor, $M_{sys}$ represents the maximal response of the system, $K_{sp}$ represents the sensitivity constant of the transduction mechanism, and $[DR_{a}GX]$ represents the amount of the active state of the agonist receptor complex ($DR_{a}$) in a quaternary complex with G protein ($G$) bound with guanine nucleotide ($X$). The model is essentially equivalent to that described by Black and Leff (1983), but with the concentration of agonist-receptor complex replaced with $[DR_{a}GX]$. In addition, we have used the variable $M_{sys}$ instead of $E_{sys}$.

The model used to simulate the formation of the quaternary complex ($DRGX$) is shown in Fig. 1. The central square of equilibrium expressions in Fig. 1a represents the ternary complex model of De Lean et al. (1980), and the outer square incorporates a guanine nucleotide-binding step. Each receptor complex shown in Fig. 1a represents the summation of active and inactive states. For example, the $DRGX$ complex is equivalent to the sum of the active ($DR_{a}GX$) and inactive ($DR_{i}GX$) states. Thus, the complete model includes two layers of equilibrium expressions, each that shown in Fig. 1a but undergoing an interconversion between active ($R_{a}$) and inactive ($R_{i}$) states of the receptor complex as shown in Fig. 1b. A complete description of the constants in the model is given under Appendix as well as the equation used to generate the active state of the quaternary complex (eq. 30).

The model shown in Fig. 1b also enables the calculation of the amount of free active receptor in a complex with the G protein and guanine nucleotide ($R_{a}GX$) (eq. 51). This species represents constitutive receptor activity. In all of our simulations, we used parameter estimates that yielded insignificant constitutive activity such that the response in the absence of agonist was less than 0.65% of the maximal response of the system.

**Analysis of Theoretical and Experimental Data.** We used a modification of the operational model to analyze both theoretical and experimental agonist concentration-response curves. For estimation of the $RA_{a}$ and $K_{obs}$ values of agonist, we used global nonlinear regression analysis to fit eq. 2 to the concentration-response curve of the most efficacious agonist while simultaneously fitting eq. 3 to the concentration-response curves of the other agonists:

$$\text{response} = \frac{M_{sys}}{1 + \left(1 + 10^{\frac{log_{10}K_{R} - log_{10}R_{a}}{D}}\right)^{-m}}$$  \hspace{1cm} (2)

$$\text{response} = \frac{M_{sys}}{1 + \left(1 + 10^{\frac{log_{10}K_{R} - log_{10}R_{a}}{D}}\right)^{-m}}$$  \hspace{1cm} (3)

In these equations, $M_{sys}$ represents the maximal response of the system, $m$ represents the transducer slope factor, $D$ represents the concentration of agonist, and $K_{obs}$ represents the affinity constant of the agonist. The symbol ‘a’, is used to denote the parameters of the standard agonist. $R$ represents the product of $R_{a}$ and $R_{i}$ and $1$ is defined by eq. 20. $RA_{a}$ is a relative estimate of the product of affinity and efficacy of the agonist and its definition is given by eq. 24. All of the agonist concentration-response curves were fitted simultaneously, sharing the estimates of $M_{sys}$ and $m$ among the curves and obtaining a unique estimate of $R$ for the most efficacious agonist and unique estimates of $K_{obs}$ and $RA_{a}$ for the other agonists. The details of the fitting procedure have been described previously (Ehlert, 2008).

Fig. 1. Quaternary complex model for the interaction of orthosteric ligand ($D$) with a receptor ($R$) and G protein ($G$) that binds guanine nucleotide ($X$). a, equilibrium between the various ligand-receptor-G protein-guanine nucleotide complexes of the quaternary complex model. b, in this scheme, the active ($R_{a}$) and inactive ($R_{i}$) states of each receptor complex in the quaternary complex model are shown. The microscopic affinity constants of $D$ for the active ($K_{a}$) and inactive ($K_{i}$) states of the receptor are defined by eqs. 45 and 44, respectively.
For the estimation of RI and \( K_a \) values, each agonist concentration-response curve was fitted to the following equation by nonlinear regression analysis:

\[
\text{response} = \frac{M_{\text{sys}}}{1 + \left( 10^{\log K_{\text{sys}} + \log K_{\text{obs}}} \right)^m} \tag{4}
\]

In this equation, \( \varepsilon \) represents efficacy, and \( K_{\text{obs}} \) is a measure of the sensitivity of the signaling pathway as described below in connection with eq. 20. Equation 4 was derived by taking the operational model (eq. 18), substituting in eq. 20 for \( \varepsilon \), and expressing the parameters in logarithmic form. During regression analysis, the values of \( M_{\text{sys}}, K_{\text{obs}}, \) and \( m \) were constrained to the estimates obtained from the RA analysis. Repetitive regression analyses were done, each time constraining \( K_{E-\text{obs}} \) to a constant so that the upper limit of the domain of \( K_{E-\text{obs}} \) values that yielded a least-squares fit was identified. The estimate of \( \log K \) for the active and inactive states are denoted by \( D \) and \( K_a \), respectively. The constant describing the spontaneous interconversion of the agonist-receptor complex in the active state (observed efficacy, \( \varepsilon \)). It has been shown that the function describing the stimulus-sensitivity of the signaling pathway as described below in connection with eqs. 8, 21, 23, and 26 as described under Results.

**Results**

**Receptor Theory**

A Relative Estimate of Agonist Affinity for the Inactive State of the Receptor. Our thesis is that the product of \( K_{\text{obs}} \) and the fraction of the agonist-receptor complex in the active state is proportional to the microscopic affinity constant of the agonist for the inactive state of the receptor. If correct, this hypothesis should be easy to prove for a simple system, consisting of a receptor in equilibrium between active (\( R_a^* \)) and inactive states (\( R_a \)). This simple model is shown in Scheme 1, in which the affinity constants of the agonist (\( D \)) for the active and inactive states are denoted by \( K_a \) and \( K_a^* \), respectively, and \( K_c \) denotes the unimolecular constant describing the equilibrium between the receptor states. Our analysis applies to the condition in which there is little constitutive receptor activity (\( K_c \ll 1 \)).

To prove our hypothesis for the model in Scheme 1, we first derive expressions for observed affinity and the fraction of the agonist-receptor complex in the active state (observed efficacy, \( \varepsilon \)). It has been shown that the function describing the amount of agonist-receptor complex in the active state (\( DR_{a^*} \)) is given by Tran et al. (2009):

\[
DR_{a^*} = \frac{\varepsilon DR_T}{D + K_{\text{obs}}} \tag{5}
\]

In this equation \( D \) denotes the concentration of agonist, \( R_T \) denotes the total concentration of receptors, \( \varepsilon \) denotes the efficacy of the agonist, and \( K_{\text{obs}} \) denotes the observed affinity constant of the agonist (reciprocal of the observed dissociation constant). This function is also known as the stimulus (\( S \)) as described by Furchgott (1966) and Stephenson (1956) in nearly equivalent forms. \( K_{\text{obs}} \) for the receptor is given by the following equation as described previously (Tran et al., 2009):

\[
K_{\text{obs}} = \frac{K_a + K_bK_c}{1 + K_c} \tag{6}
\]

Efficacy is equivalent to the fraction of the agonist-receptor complex in the active state. This can be determined at 100% receptor occupancy by taking the limit of the receptor activation function as the agonist concentrations approaches saturating levels as described previously (Tran et al., 2009):

\[
\varepsilon = \frac{1}{1 + \frac{K_a}{K_a^*}} \tag{7}
\]

The fraction of the agonist-receptor complex in the inactive state (\( \varepsilon_i \)) is equivalent to

\[
\varepsilon_i = 1 - \varepsilon \tag{8}
\]

We define \( \varepsilon_i \) as the intrinsic inactivity of the agonist-receptor complex. Substituting in eq. 7 for \( \varepsilon \) in eq. 8 followed by simplification yields

\[
\varepsilon_i = \frac{1}{1 + \frac{K_a}{K_a^*}} \tag{9}
\]

The product of \( K_{\text{obs}} \) and \( \varepsilon_i \) of one agonist expressed relative to that of another standard agonist is equivalent to

\[
K_{\text{obs}}\varepsilon_i \overset{\text{standard}}{=} \frac{K_a + K_bK_c}{1 + K_a^*} \times \frac{1}{1 + K_c} \times \frac{1}{K_c} \tag{10}
\]

in which the parameters of the standard agonist are denoted with °. The right side of this equation was derived by taking the expression on the left side and substituting in eqs. 6 and 9 for \( K_{\text{obs}} \) and \( \varepsilon_i \), respectively. Further simplification yields

\[
\frac{K_{\text{obs}}\varepsilon_i}{\text{standard}} = \frac{K_a}{K_a^*} \tag{11}
\]

This equation shows that if a receptor conforms to Scheme 1, then the product of observed affinity and intrinsic inactivity of one agonist expressed relative to that of another is equivalent to the corresponding ratio of microscopic affinity constants for the inactive state of the receptor. We define this term as the intrinsic relative inactivity of the agonist (RI).
Figure 2 illustrates the relationship between $R_I$, and the product $K_{obs} \varepsilon_i$ for two agonists. Also shown is the relationship between $R_A$, and the product of $K_{obs} \varepsilon_i$, which is described by eq. 24.

**Estimation of the $K_a$ Value in Units of Inverse Molarity.** If the receptor lacks appreciable constitutive activity, then it is usually possible to obtain an accurate estimate of the $K_a$ value. In such instances, the $K_a$ value is approximately equal to the product of $K_{obs}$ and $\varepsilon_i$ as shown by eqs. 12 to 15:

$$
K_{obs} \varepsilon_i = \frac{K_a + K_b K_e}{1 + K_e + K_b} \times \frac{1}{1 + K_e K_b} (12)
$$

The right side of this equation was derived by substituting in eqs. 6 and 9 for $K_{obs}$ and $\varepsilon_i$ on the left side, respectively. Rearrangement yields

$$
K_{obs} \varepsilon_i = \frac{K_a + K_b K_e}{1 + K_e + K_b} (13)
$$

When there is little constitutive activity, $K_e \ll 1$, and, consequently, eq. 13 can be approximated by

$$
K_{obs} \varepsilon_i \approx \frac{K_a + K_b K_e}{1 + K_b} (14)
$$

This equation reduces to

$$
K_{obs} \varepsilon_i \approx K_a (15)
$$

**Modification of the Operational Model for Estimation of $R_I$ and $K_a$.** Most assays for agonist activity at G protein-coupled receptors involve the measurement of a response downstream from receptor activation and not receptor activation itself. To estimate $R_I$ or $K_a$, therefore, it is necessary to incorporate the theory described above into an equation that expresses the response as a function of the parameters $K_{obs}$ and $\varepsilon$. We use the reverse engineering approach described by Black and Leff (1983). These investigators showed that if the initial input to a receptor transduction mechanism is consistent with the receptor activation function (eq. 5) and the output (response, $y$) is a logistic function similar to

$$
y = \frac{D^p F_{max}}{D^p + EC_{50}^n} (16)
$$

then the equation that expresses the response ($y$) as a function of the stimulus (eq. 5) is

$$
y = \frac{S^n M_{sys}}{S^n + K_E^m} (17)
$$

In eq. 16, $n$ represents the slope factor of the concentration-response curve, $P_{max}$ represents the maximal response, and $EC_{50}$ represents the concentration of agonist eliciting a half-maximal response. In eq. 17, $S$ denotes the active agonist-receptor complex ($DR^a$), $M_{sys}$ denotes the maximal response of the system, $K_E$ denotes the sensitivity constant of the system, and $m$ denotes the transducer-slope factor. Substituting in eq. 5 for $S$ in eq. 17 yields the following equation after simplification:

$$
y = \frac{M_{sys}}{1 + \left(\frac{DK_{obs}}{DK_{obs} + 1}\right)^m} (18)
$$

in which

$$
\tau = \frac{\varepsilon R_T}{K_E} (19)
$$

This equation for $\tau$ can be written in a simpler form by substituting in $K_{E,obs}$ for the ratio $K_E/R_T$:

$$
\tau = \frac{\varepsilon}{K_{E,obs}} (20)
$$

We define $\tau_i$ as

$$
\tau_i = \frac{\varepsilon_i}{K_{E,obs}} (21)
$$

It follows that the product of $K_{obs} \varepsilon_{i}$ of one agonist expressed relative to that of a standard agonist is equivalent to the corresponding ratio of products of observed affinity and intrinsic inactivity:

$$
R_A = \frac{\varepsilon K_{obs}}{\varepsilon K_{obs}} = \frac{K_b}{K_b} (22)
$$

$$
R_I = \frac{\varepsilon K_{obs}}{\varepsilon K_{obs}} = \frac{K_a}{K_a} (23)
$$

Fig. 2. Relationship between the stimulus and efficacy ($\varepsilon$), intrinsic inactivity ($\varepsilon_j$), the observed affinity constant ($K_{obs}$), and the affinity constants of the active ($K_a$) and inactive ($K_b$) states of the receptor. The theoretical plots show the amount of agonist bound to the active state of the receptor ($DR^a$) for two agonists, $D$ and $D'$. The curves are based on the model shown in Scheme 1 and were derived using eqs. 5 to 7. The maximal amounts of the active and inactive states of the agonist-receptor complexes are denoted $\varepsilon$ and $\varepsilon_j$, respectively. $R_A$ is a relative measure of the product of affinity and efficacy of one agonist ($D$) expressed relative to that of another ($D'$), whereas $R_I$ is a relative measure of the product of affinity and intrinsic inactivity. The mathematics described by eqs. 24 and 11 show that $R_A$ and $R_I$ are relative measures of the microscopic affinity constants of the active ($K_a'/K_a$) and inactive ($K_b'/K_b$) states of the receptor, respectively.
We simulated curves for agonist receptor activation (DRsponse curves) to estimate the operational model as shown by the next two equations:

\[ \frac{K_{\text{obs} \tau_1}}{K_{\text{obs} \tau_1}^{*}} = \frac{K_{\text{obs} \tau_1}}{K_{\text{obs} \tau_1}^{*}} = \frac{K_\alpha}{K_\beta} = \text{RI}_i \]  

Again, the * is used to designate the parameters of the standard agonist. From eq. 11, it follows that

\[ \frac{K_{\text{obs} \tau_1}}{K_{\text{obs} \tau_1}^{*}} = \frac{K_a}{K_a} = \text{RI}_i \]  

We have previously shown an analogous relationship between the product of observed affinity and efficacy and the ratio of microscopic affinity constants of the active state of the receptor (Tran et al., 2009):

\[ \frac{K_{\text{obs} \tau}}{K_{\text{obs} \tau}} = \frac{K_{\text{obs} \tau}}{K_{\text{obs} \tau}} = \frac{K_b}{K_b} = \text{RA}_i \]  

This ratio is known as the intrinsic relative activity of the agonist (RAi).

When there is little constitutive activity, it is possible to estimate the Kα value of the agonist from the parameters of the operational model as shown by the next two equations:

\[ K_{E \text{-obs}} K_{\text{obs} \tau_1} = K_{\text{obs} \tau_1} \]  

The right side of eq. 25 was generated from the left side by substituting in eq. 21 for τ and simplifying. When there is little constitutive activity, the right side of the equation can be replaced with Kα as shown by eq. 15:

\[ K_{E \text{-obs}} K_{\text{obs} \tau_1} = K_\alpha \]  

**Analysis of Simulated Agonist Concentration-Response Curves.** Another approach for proving that the product Kobs τ1 is proportional to the microscopic affinity constant of the agonist for the inactive state of the receptor is to generate theoretical agonist concentration-response curves using the operational model and to determine whether it is possible to obtain accurate estimates for the RI, and Kα values from the theoretical data. A robust way to simulate the data is to generate the receptor-activation function using the ternary complex model with guanine nucleotide (quaternary complex model) defined at the level of receptor states.

We have previously explained that the ratio of microscopic affinity constants of the active state of the receptor (Tran et al., 2009):

\[ \frac{K_{\text{obs} \tau}}{K_{\text{obs} \tau}} = \frac{K_{\text{obs} \tau}}{K_{\text{obs} \tau}} = \frac{K_b}{K_b} = \text{RA}_i \]  

This ratio is known as the intrinsic relative activity of the agonist (RAi). When there is little constitutive activity, it is possible to estimate the Kα value of the agonist from the parameters of the operational model as shown by the next two equations:

\[ K_{E \text{-obs}} K_{\text{obs} \tau_1} = K_{\text{obs} \tau_1} \]  

The right side of eq. 25 was generated from the left side by substituting in eq. 21 for τ and simplifying. When there is little constitutive activity, the right side of the equation can be replaced with Kα as shown by eq. 15:

\[ K_{E \text{-obs}} K_{\text{obs} \tau_1} = K_\alpha \]  

**Analysis of Agonist Concentration-Response Curves When the Intracelluar Concentration of GTP Is High and the Transducer Slope Factor Equals One (m = 1).** We simulated curves for agonist receptor activation (DRs*GX) under conditions in which the concentration of guanine nucleotide is high (X = 10⁻³ M), because GTP is often present in cells at concentrations that saturate G proteins. For these simulations, the affinity constant of each agonist for the inactive state (Kα) was set to a constant value (Kα = 10⁵ M⁻¹) and that for the active state (Kβ) was varied to yield Kβ/Kα ratios of 100,000, 10,000, 1000, 100, and 10 for agonists A to E, respectively. The amount of agonist bound in the form of quaternary complex was estimated using eq. 30 as described under Appendix. The resulting receptor activation curves (stimulus function) are shown in Fig. 3, a and b. The complete set of parameters for the simulations is listed in the legend to Fig. 3. With these parameters, the amount of spontaneous receptor activation was very low in the absence of agonist (DRs*GX = 0.013%), which yielded a basal response of only 0.65%. The maximal fractional amount of the DRs*GX complex is equivalent to ε, and the reciprocal of the concentration of agonist causing a half-maximal formation of DRs*GX is equivalent to Kobs. The values of Kα, Kβ, Kα/Kβ, Kobs, and a relative estimate of ε are listed for each agonist in Table 1.

The simulated stimulus curves were used as input to the operational model, and theoretical agonist concentration-response curves were generated using eq. 1, with Msys = 100%, Kobs = 0.02, and m = 1. A random error (±5%) was added to the simulated data, and the resulting curves are illustrated in Fig. 3c. The EC50 and Emax values of the agonists were estimated by nonlinear regression analysis of the data using eq. 16, and these estimates are listed in Table 2.

The first step in the analysis of the simulated data involves estimation of the agonist RAi values by global nonlinear regression analysis using eqs. 2 and 3 as described previously (Ehlert, 2008). This analysis also yields estimates of the Kα values of the partial agonists. The log RAi values were first estimated relative to the most efficacious agonist (0.00, –1.05, –1.99, –3.01, and –3.99 for agonists A to E, respectively). These values are listed in Table 1, normalized to the least efficacious agonist. For each agonist, there is reasonable agreement between log RAi and the log ratio of its Kα value expressed relative to that of the least efficacious agonist (Kα'). This regression analysis also yielded estimates of Msys (98.6%) and m (1.00).

The estimation of RI and Kα requires estimates of the Kobs values of the full agonists. We used the theoretical values for the full agonists A and B, but with real experimental data, it would be necessary to estimate Kobs using the method of partial receptor inactivation.

The first step in the estimation of RI and Kα involves determination of the maximal value of Kobs that yields a least-squares fit of eq. 4 to the concentration-response curve of the most efficacious agonist (agonist A). Equation 4 is essentially the operational model with τ expressed as the ratio ε/Kobs. Regression analysis is done with the log Kobs value of agonist A constrained to its estimated value (theoretical value of 5.0 in this case). The parameters Msys and m are constrained to the values estimated in the RAi analysis described above. The parameter log Kobs is constrained to an arbitrarily low value (e.g., –4). The parameter ε is constrained to the range 0 < ε < 1.0 (i.e., log ε < 0), because for a real receptor, ε can only assume values between 0 and 1. Regression analysis is initiated, and the estimate of log ε that yields a least-squares fit is determined. This process is repeated iteratively, constraining log Kobs to higher values for
Fig. 3. Analysis of simulated agonist concentration-response curves. Agonist concentration-response curves were generated by first calculating the stimulus (a and b) using eq. 30 under Appendix with the concentration of guanine nucleotide high ($X = 1.0 \text{ mM}$). This stimulus was used as input to the operational model (eq. 1) to yield the response as a function of the agonist concentration (c). d, nonlinear regression analysis of the concentration-response curve of agonist A using eq. 4. The points show the estimates of log $R_{i}^{A}$, log $\epsilon$, and the RSS plotted against the value to which $K_{E-obs}$ was constrained during regression analysis. A least-squares fit was obtained whenever log $K_{E-obs} \leq -1.55$. The affinity constants of the agonists (A–E) for the inactive state of the receptor were the same ($K_{E} = 10^{5} \text{ M}^{-1}$). Those for the active state ($K_{E}^{*}$) were $10^{2}$, $10^{3}$, $10^{4}$, and $10^{5}$, respectively, as indicated by the $K_{E}/K_{E}^{*}$ ratios in a and b. The microscopic state constants for the quaternary complex model were log $K_{m} = -2.15$; log $K_{g} = 2.85$; log $K_{k} = 8.00$; log $K_{s} = 4.60$; and log $K_{m} = -4.30$. The ratio of G protein to receptor was 10, and the receptor concentration was 1.0 unit. The parameters of the operational model were $M_{sys} = 100$; $m$, 1.0; and log $K_{gs}$, -1.7.

TABLE 1
Theoretical and estimated parameters for the agonist concentration-response curves shown in Fig. 3

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Log $K_{g}$</th>
<th>Log $K_{k}$</th>
<th>Log $K_{m}/K_{m}^{*}$</th>
<th>Log $K_{s}$</th>
<th>Relative Efficacy</th>
<th>Log $K_{E}^{*}$</th>
<th>Log $R_{i}^{A}$</th>
<th>Log $R_{A}^{c}$</th>
<th>Log $K_{E-obs}$</th>
<th>Relative $\tau_{d}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>5.0</td>
<td>10.0</td>
<td>4.0</td>
<td>0.0</td>
<td>1.00</td>
<td>4.93</td>
<td>-0.077</td>
<td>3.99</td>
<td>N.D.</td>
<td>1.00</td>
</tr>
<tr>
<td>B</td>
<td>5.0</td>
<td>9.0</td>
<td>3.0</td>
<td>5.45</td>
<td>0.68</td>
<td>5.07</td>
<td>-0.059</td>
<td>2.95</td>
<td>N.D.</td>
<td>0.62</td>
</tr>
<tr>
<td>C</td>
<td>5.0</td>
<td>8.0</td>
<td>2.0</td>
<td>5.08</td>
<td>0.16</td>
<td>5.01</td>
<td>-0.013</td>
<td>2.01</td>
<td>5.10</td>
<td>0.15</td>
</tr>
<tr>
<td>D</td>
<td>5.0</td>
<td>7.0</td>
<td>1.0</td>
<td>5.01</td>
<td>0.019</td>
<td>5.00</td>
<td>-0.019</td>
<td>0.98</td>
<td>5.00</td>
<td>0.018</td>
</tr>
<tr>
<td>E</td>
<td>5.0</td>
<td>6.0</td>
<td>0.0</td>
<td>5.00</td>
<td>0.0019</td>
<td>5.00</td>
<td>0.00</td>
<td>5.00</td>
<td>5.00</td>
<td>0.0017</td>
</tr>
</tbody>
</table>

N.D., not determined.

* Represents the log reciprocal of the agonist concentration required for half-maximal formation of the quaternary complex.

† Represents the maximal amount of $DR_{i}^{*}$ complex formed by the agonist, expressed relative to that of agonist A.

‡ Expressed relative to that of agonist E.

§ Expressed relative to that of agonist A.

TABLE 2
Estimation of $R_{i}$, $K_{E-obs}$, and relative efficacy using eqs. 27 to 29, respectively.

The parameters were estimated from the EC$_{50}$ and $E_{max}$ values of the concentration-response curves shown in Fig. 3. For the calculations, it was assumed that the $E_{max}$ of agonist A was a good estimate of $M_{sys}$.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Log EC$_{50}$</th>
<th>$E_{max}$</th>
<th>Log RA</th>
<th>Log $K_{obs}$</th>
<th>Relative Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>-7.83</td>
<td>1.00</td>
<td>4.00</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>B</td>
<td>-6.79</td>
<td>0.99</td>
<td>2.95</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>C</td>
<td>-5.91</td>
<td>0.85</td>
<td>2.01</td>
<td>5.10</td>
<td>1.00</td>
</tr>
<tr>
<td>D</td>
<td>-5.21</td>
<td>0.40</td>
<td>0.98</td>
<td>4.99</td>
<td>0.12</td>
</tr>
<tr>
<td>E</td>
<td>-5.03</td>
<td>0.063</td>
<td>0.00</td>
<td>5.01</td>
<td>0.012</td>
</tr>
</tbody>
</table>

N.D., not determined.

* The estimate of $E_{max}$ is expressed relative to that of agonist A.

† Expressed relative to that of agonist E.

‡ Expressed relative to that of agonist C.

each regression until the maximal value of log $K_{E-obs}$ that yields a least-squares fit is determined.

A summary of this iterative procedure is shown in Fig. 3d for agonist A. The plot shows that the residual sum of squares (RSS) for the regression is at a minimum whenever log $K_{E-obs}$ is constrained to a value less than -1.55.

This process was also done for agonists B to D, and the results are shown in Fig. 4. The vertical dashed lines in Fig. 4 correspond to the maximal value of log $K_{E-obs}$ that yields a least-squares fit for agonist A (log $K_{E-obs} = -1.55$). The estimates of log $\epsilon$ when log $K_{E-obs}$ is constrained to its upper limit (-1.55) were -0.02, -0.23, -0.84, -1.77, and -2.78 for agonists A to E, respectively.

With these estimates of $\epsilon$, it is possible to estimate $\epsilon_{i}$ using eq. 8. Then, $\tau_{d}$ is estimated from $\epsilon_{i}$ using eq. 21. Finally, $R_{i}$ and $K_{i}$ are estimated from $\tau_{d}$ and $K_{E-obs}$ using eqs. 23 and 26, respectively. The relationship between log $R_{i}$ and log $K_{E-obs}$ is also shown in Fig. 3d (agonist A) and Fig. 4 (agonists B to D). For agonists B to D, the estimate of log $R_{i}$ is approximately equal to the true value (log $R_{i} = 0$) when log $K_{E-obs} = -1.55$. For agonists C and D, the estimate of log $R_{i}$ is constant over the range log $K_{E-obs} \leq -1.55$. For all the agonists, the estimate of log $R_{i}$ is equivalent to the corresponding ratio of $K_{obs}$ values when log $K_{E-obs}$ is very low.
The estimates of log RI and log $K_a$ are listed in Table 1. There is general agreement between these estimates and the theoretical values used to generate the data (i.e., log RI = 0 and log $K_a = 5$). Although the estimates of log RI and log $K_a$ are accurate, the values of log $K_{E-obs}$, $\varepsilon$, and $\varepsilon'$ are unreliable.

The lengthy iteration procedure summarized in Figs. 3d and 4 was described to verify and explain the relationship between log $K_{E-obs}$ and the estimates of log RI and log $K_a$. However, the maximal estimate of log $K_{E-obs}$ for the most efficacious agonist can be determined more quickly by regression analysis with eq. 4 with the parameters constrained as described above except that $\varepsilon$ is constrained to 1.0 (log $\varepsilon = 0$) and log $K_{E-obs}$ is unconstrained. The resulting estimate of log $K_{E-obs}$ is a little larger than the maximal value that yields a least-squares fit (−1.55). The latter can be determined by constraining log $K_{E-obs}$ to nearby smaller values as described above in connection with Fig. 3d. It is unnecessary to do the regression with the less efficacious agonists.

When the transducer slope factor in the operational model (m) is equivalent to one, the slope factor of the agonist concentration-response curve (n) is also equivalent to one, and there are simple relationships among the EC50 and $E_{max}$ values of agonists and the parameters RAi, $K_{obs}$, and relative efficacy (eqs. 27–39). Under this condition (i.e., m = 1), RAi is described by the following equation (Ehlert et al., 1999):

$$RA_i = \frac{E_{max} \epsilon}{E_{max} EC_{50}}$$  (27)

The $\epsilon$ is used to designate the parameters of the standard agonist. It can also be shown that the $K_{obs}$ value of an agonist can be estimated by (see Appendix, eq. 56):

$$K_{obs} = \frac{1 - E_{max}}{EC_{50}}$$  (28)

Finally, the relative efficacy of agonists can be estimated by (see Appendix, eqs. 57–59):

$$\frac{\varepsilon}{\varepsilon'} = \frac{E_{max}(M_{sys} - E_{max})}{E_{max}(M_{sys} - E_{max})}$$  (29)

Practically speaking, eqs. 28 and 29 can only be applied to the analysis of partial agonists, because there is little difference between $E_{max}$ and $M_{sys}$ for full agonists. These equations yielded reasonably accurate estimates of the corresponding parameters for the partial agonists as illustrated in Table 2.

**Analysis of Agonist Concentration-Response Curves When the Intracellular Concentration of GTP is Low and the Transducer Slope Factor Equals One (m = 1).**

We also considered the condition in which the concentration of guanine nucleotide is low. These simulations were performed as described above for the data in Fig. 3 except that the concentration of guanine nucleotide (X) was set to a lower value of 1.8 μM. Figure 5 shows the results of these simulations. The reduction in X caused an increase in the value of $K_{obs}$ and a decrease in the maximal amount of $DR^*_sGX$ for each agonist (Fig. 5a; Table 3). The reduction in efficacy was offset by the increase in affinity such that there was little change in the agonist concentration-response curves except for an overall decrease in $E_{max}$ (Fig. 5b). The EC50 and $E_{max}$ values of the curves are listed in Table 4. The RA values of the agonists were estimated by global nonlinear regression analysis using eqs. 2 and 3, and these estimates are listed in Table 3.
The agonist-concentration response curves were also analyzed by regression analysis using eq. 4 to estimate the $RI_i$ and $K_a$ values of the agonists using the procedure described above. A least-squares fit was obtained for the most efficacious agonist when the estimate of $K_{E-obs}$ was constrained over the domain $K_{G-Eobs} \leq -0.50$. The concentration-response curves of the less efficacious agonists were analyzed by eq. 4 with $K_{E-obs}$ constrained to $-0.50$. The resulting estimates of $\varepsilon$ for each agonist were used to estimate $RI_i$ and $K_a$ as described above. These values are listed in Table 3. There is general agreement between the $RA_i$, $RI_i$, and $K_a$ estimates and the corresponding theoretical values ($K_b/K_a$, $K_d/K_a$, and $K_e$) used to generate the data. For the partial agonists, there was also good agreement between the theoretical values of $RA_i$, $K_{obs}$, and relative efficacy and the corresponding estimates determined from the $EC_{50}$ and $E_{max}$ values using eqs. 27 to 29 (Table 4).


table 3

<table>
<thead>
<tr>
<th>Agonist</th>
<th>$Log K_a$</th>
<th>$Log K_b$</th>
<th>$Log K_b/K_a$</th>
<th>$Log K_{obs}$</th>
<th>Relative Efficacy</th>
<th>$Log K_a$</th>
<th>$Log RI_i$</th>
<th>$Log RA_i$</th>
<th>$Log K_{obs}$</th>
<th>Relative $\tau^d$</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>5.0</td>
<td>10.0</td>
<td>4.0</td>
<td>7.28</td>
<td>1.00</td>
<td>4.95</td>
<td>-0.028</td>
<td>4.10</td>
<td>N.D.</td>
<td>1.00</td>
</tr>
<tr>
<td>B</td>
<td>5.0</td>
<td>9.0</td>
<td>3.0</td>
<td>6.30</td>
<td>0.95</td>
<td>4.95</td>
<td>-0.034</td>
<td>3.06</td>
<td>N.D.</td>
<td>0.98</td>
</tr>
<tr>
<td>C</td>
<td>5.0</td>
<td>8.0</td>
<td>2.0</td>
<td>5.47</td>
<td>0.66</td>
<td>5.01</td>
<td>0.013</td>
<td>2.07</td>
<td>5.39</td>
<td>0.66</td>
</tr>
<tr>
<td>D</td>
<td>5.0</td>
<td>7.0</td>
<td>1.0</td>
<td>5.08</td>
<td>0.16</td>
<td>5.01</td>
<td>0.008</td>
<td>1.06</td>
<td>5.00</td>
<td>0.16</td>
</tr>
<tr>
<td>E</td>
<td>5.0</td>
<td>6.0</td>
<td>0.0</td>
<td>5.01</td>
<td>0.020</td>
<td>5.00</td>
<td>0.000</td>
<td>0.00</td>
<td>5.00</td>
<td>0.018</td>
</tr>
</tbody>
</table>

| N.D., not determined. |
| $\footnote{\text{a} \text{ Represents the log reciprocal of the agonist concentration required for half-maximal formation of the } DR_1^{\text{G}X} \text{ complex.}}$ |
| $\footnote{\text{b} \text{ Represents the maximal amount of } DR_1^{\text{G}X} \text{ complex formed by the agonist, expressed relative to that of agonist A.}}$ |
| $\footnote{\text{c} \text{Expressed relative to that of agonist E.}}$ |
| $\footnote{\text{d} \text{Expressed relative to that of agonist A.}}$ |

Table 4

<table>
<thead>
<tr>
<th>Agonist</th>
<th>$Log EC_{50}$</th>
<th>$E_{max}$</th>
<th>$Log RA_i$</th>
<th>$Log K_{obs}$</th>
<th>Relative Efficacy</th>
<th>$Log K_a$</th>
<th>$Log RI_i$</th>
<th>$Log RA_i$</th>
<th>$Log K_{obs}$</th>
<th>Relative $\tau^d$</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>-7.95</td>
<td>1.00</td>
<td>4.02</td>
<td>N.D.</td>
<td>N.D.</td>
<td>-7.95</td>
<td>-0.67</td>
<td>4.02</td>
<td>N.D.</td>
<td>1.00</td>
</tr>
<tr>
<td>B</td>
<td>-6.91</td>
<td>1.00</td>
<td>2.98</td>
<td>N.D.</td>
<td>N.D.</td>
<td>-6.91</td>
<td>-0.57</td>
<td>2.98</td>
<td>N.D.</td>
<td>1.00</td>
</tr>
<tr>
<td>C</td>
<td>-5.98</td>
<td>0.90</td>
<td>2.00</td>
<td>5.00</td>
<td>1.00</td>
<td>-5.98</td>
<td>-0.57</td>
<td>2.00</td>
<td>5.00</td>
<td>1.00</td>
</tr>
<tr>
<td>D</td>
<td>-5.29</td>
<td>0.45</td>
<td>1.02</td>
<td>5.03</td>
<td>0.096</td>
<td>-5.29</td>
<td>-0.57</td>
<td>1.02</td>
<td>5.03</td>
<td>0.096</td>
</tr>
<tr>
<td>E</td>
<td>-5.03</td>
<td>0.079</td>
<td>0.00</td>
<td>4.99</td>
<td>0.010</td>
<td>-5.03</td>
<td>-0.57</td>
<td>0.00</td>
<td>4.99</td>
<td>0.010</td>
</tr>
</tbody>
</table>

| N.D., not determined. |
| $\footnote{\text{a} \text{ The estimate of } K_{Eobs} \text{ is expressed relative to that of agonist A.}}$ |
| $\footnote{\text{b} \text{Expressed relative to that of agonist E.}}$ |
| $\footnote{\text{c} \text{Expressed relative to that of agonist C.}}$ |

Analysis of Agonist Concentration-Response Curves When the Intracellular Concentration of GTP Is High and the Transducer Slope Factor Greater Than One. We also considered theoretical data derived from the operational model with a transducer slope factor greater than one (i.e., $m = 1.8$). The theoretical microscopic constants for these simulations are listed in Table 5, and the corresponding receptor activation functions are shown in Fig. 6, a and b. The theoretical concentration-response curves were generated using the operational model with a $K_{E-obs}$ value of 0.02, and the resulting curves are shown in Fig. 6c. The $EC_{50}$, $E_{max}$, and slope factors ($\alpha$) of the agonists were estimated from the theoretical concentration-response curves, and these values are listed in Table 6. The $K_{obs}$, $RA_i$, $RI_i$, and $K_a$ values were estimated by nonlinear regression analysis using the approach described above for the analysis of the data in Fig. 3, and the resulting parameter estimates are listed in Table 5. There was general agreement between these estimates and the corresponding theoretical values that were used to generate the theoretical data. The largest error (approximately 3-fold) was in the estimate of $K_a$ and $RI_i$ for the most efficacious agonist.

Other Simulations. We also examined a variety of other conditions including a change in the ratio of G protein to receptor and a variation in the sensitivity constant of the transducer function ($K_E$). In each case, we obtained reliable estimates of $RA_i$, $RI_i$, and $K_a$ of all but the most efficacious agonist in a series.

Analysis of Experimental Data We analyzed some of our prior data on muscarinic agonist stimulation of phosphoinositide hydrolysis in Chinese ham-
Fig. 6 Simulated stimuli (a and b) and agonist concentration-response curves (c) for the condition of a transducer slope factor greater than 1 \((m = 1.8)\). The stimuli were generated using eq. 30 under Appendix with the concentration of guanine nucleotide set to a high value \((X = 1.0 \text{ mM})\). The stimulus was then used as input to the operational model (eq. 1) to yield the response as a function of the agonist concentration. The affinity constants of the agonists \((A–G)\) for the inactive state of the receptor were the same \((K_a = 10^3 \text{ M}^{-1})\). Those for the active state \((K_a)\) were \(3 \times 10^6, 3 \times 10^3, 3 \times 10^6, 3 \times 10^7, 10^5\), and \(3 \times 10^7\), respectively, as indicated by the \(K_a/K_\text{obs}\) ratios in a and b. The other parameters were the same as those given in the legend to Fig. 3 except that the value of the transducer slope factor in the operational model \((m)\) was 1.8. The basal response caused by constitutive receptor activity was only 0.011% for this simulation. 

![Diagram](image_url)

Table 6 Estimated parameters for the agonist concentration-response curves shown in Fig. 6

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Estimated Parameters</th>
<th>Slope Factor ((m))</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1.00</td>
<td>–8.25</td>
</tr>
<tr>
<td>B</td>
<td>0.998</td>
<td>–7.25</td>
</tr>
<tr>
<td>C</td>
<td>0.992</td>
<td>–6.25</td>
</tr>
<tr>
<td>D</td>
<td>0.94</td>
<td>–5.72</td>
</tr>
<tr>
<td>E</td>
<td>0.74</td>
<td>–5.18</td>
</tr>
<tr>
<td>F</td>
<td>0.30</td>
<td>–4.84</td>
</tr>
<tr>
<td>G</td>
<td>0.050</td>
<td>–4.62</td>
</tr>
</tbody>
</table>

*\(E_{\text{max}}\) is normalized relative to that of agonist A.

Table 7 Estimated parameters for the agonist concentration-response curves shown in Fig. 7

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Estimated Parameters</th>
<th>Log (K_a)</th>
<th>Log (R_\text{A})</th>
<th>Log (K_{\text{obs}})</th>
<th>Relative *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxotremore-M</td>
<td>N.D.</td>
<td>2.01</td>
<td>5.46</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Oxotremore-M</td>
<td>5.86</td>
<td>0.74</td>
<td>1.77</td>
<td>6.02</td>
<td>0.16</td>
</tr>
<tr>
<td>Carbachol</td>
<td>5.17</td>
<td>–0.05</td>
<td>1.43</td>
<td>5.31</td>
<td>0.37</td>
</tr>
<tr>
<td>Arecoline</td>
<td>5.44</td>
<td>0.22</td>
<td>1.37</td>
<td>5.51</td>
<td>0.20</td>
</tr>
<tr>
<td>S-Aceclidine</td>
<td>5.35</td>
<td>0.13</td>
<td>1.13</td>
<td>5.40</td>
<td>0.15</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>5.54</td>
<td>0.32</td>
<td>0.75</td>
<td>5.55</td>
<td>0.044</td>
</tr>
<tr>
<td>R-Aceclidine</td>
<td>5.01</td>
<td>–0.21</td>
<td>0.38</td>
<td>5.03</td>
<td>0.063</td>
</tr>
<tr>
<td>Bethanechol</td>
<td>4.09</td>
<td>–1.13</td>
<td>0.27</td>
<td>4.21</td>
<td>0.32</td>
</tr>
<tr>
<td>McN-A-343</td>
<td>5.22</td>
<td>0.00</td>
<td>0.00</td>
<td>5.23</td>
<td>0.017</td>
</tr>
</tbody>
</table>

*Not determined.

*Expressed relative to that of McN-A-343.

Fig. 7 Muscarinic agonist stimulated phosphoinositide hydrolysis in CHO cells expressing the human \(M_3\) muscarinic receptor. a and b, concentration-response curves of various muscarinic agonists. c, corresponding estimates of log \(R_A\), log \(R_I\), and their ratio, log \(RA/RI\). The data in a and b are from Ehler et al. (1999) and represent the mean increase in \(^{3}H\)inositol phosphates, expressed relative to basal accumulation in the absence of agonist. Mean values ± S.E.M. from four experiments are shown.
are listed in Table 8 for all of the agonists. There was little difference between the parameter values when estimated using the latter method or by regression analysis using eq. 4 (Table 7).

A plot of the log $R_{A\alpha}$, $R_\text{obs}$, and $R_{A\alpha}/R_\text{obs}$ ratios of each agonist expressed relative to that of the least efficacious agonist \textit{[4-(m-chlorophenyl-carbamoyloxy)-2-butylnitrim-ethylammonium (McN-A-343)]} is shown in Fig. 7c. For oxotremorine-M, the log $K_a$ and $R_\text{obs}$ are not given, because of the error in the estimation of $K_a$. There was much greater variation in the $R_{A\alpha}$ compared with the $R_\text{obs}$. The ratio $R_{A\alpha}/R_\text{obs}$ is a relative measure of the selectivity of the agonist for the active state relative to the inactive state. This estimate for the most efficacious agonist oxotremorine-M was at least 200-fold greater than that for McN-A-343. Whereas bethanechol has approximately 10-fold lower affinity for the active and inactive states of the $M_3$ receptor compared with carbachol, it maintains a comparable degree of selectivity for the active state.

**Discussion**

In this report, we introduce the concept of the fraction of the agonist-receptor complex in the inactive state (intrinsically inactive, $\varepsilon_i$) and show that the product of $\varepsilon_i$ and $K_\text{obs}$ is proportional to the microscopic affinity constant of an orthosteric ligand for the inactive state of the receptor ($K_a$) when there is little constitutive activity. We also show that, among a group of agonists, it is possible to estimate the $K_a$ value of any agonist having an efficacy less than one-third that of the most efficacious agonist.

We have assumed that the fraction of the agonist-receptor complex in the active state coupled with the guanine nucleotide-bound form of the G protein ($D_{R^*}\text{GX}$) is an accurate measure of receptor activation for responses mediated through G proteins. The maximal amount of this quaternary complex can be substantially less than the amount of receptor, depending on the concentration of GTP, the relative amount of G protein to receptor, and the nature of their interaction. For the example shown in Fig. 3, the theoretical maximal amount of $D_{R^*}\text{GX}$ that could be formed by an agonist having a very large $K_a$/$K_\text{obs}$ ratio is only 71% of the total amount of receptor. For the example in Fig. 5, in which the concentration of GTP is only 1.8 $\mu$M, the maximum possible amount of $D_{R^*}\text{GX}$ is only approximately 6% of the amount of receptor. Thus, at G protein-coupled receptors, the maximal value that $\varepsilon$ can attain is probably substantially less than one.

When agonist receptor activation approaches the maximal limit of the system, then our method for estimating the parameter $K_{E\text{obs}}$ in eq. 4 provides an accurate means of estimating the $K_a$ value of any agonist. For example, the maximal amount of receptor activation caused by agonist A (67%) in the simulation shown in Fig. 3 is almost equivalent to the maximal limit of this theoretical simulation (71%). Using the approach described in the text, it was possible to obtain a reasonable estimate of $K_a$ through regression analysis of the concentration-response curve using eq. 4 with the value of log $K_{E\text{obs}}$ constrained to the maximal value that yields a least-squares fit (i.e., log $K_{E\text{obs}} = -1.55$). Accurate estimates of the $K_a$ values of the less efficacious agonists were also obtained when log $K_{E\text{obs}}$ was constrained to $-1.55$.

However, with real data, it could be possible that the most efficacious agonist in a series might behave like agonist C, for example, which only causes 11% receptor activation. When its concentration-response curve was analyzed, the maximal value of log $K_{E\text{obs}}$ that yielded a least-squares fit was much larger ($-0.8$). With log $K_{E\text{obs}}$ constrained to $-0.8$, the corresponding estimate of log $K_a$ (4.32) is substantially different from the true value (5.00), although the estimates of the log $K_a$ values of the less efficacious agonists (D and E) are accurate. Thus, without knowledge of the level of receptor activation caused by an agonist, we would be uncertain whether our estimate of the $K_a$ of the most efficacious agonist is accurate.

A possible solution is to examine the activity of agonists in a broken cell preparation with low concentrations of GTP and GDP (e.g., agonist-induced $[^{35}\text{S}]\text{GTP}\gamma\text{S}$ binding). Under this condition, highly efficacious agonists might cause full receptor activation as shown for the theoretical example in Fig. 5 even though the same agonists exhibit substantially different relative efficacies when the concentration of GTP is high (e.g., compare the relative efficacies of agonists A–C for the concentration-response curves in Figs. 3c and 5b). Thus, for a given receptor-G protein pair, if efficacious agonists exhibit different relative efficacies in an intact cell assay, but the same efficacy in a $[^{35}\text{S}]\text{GTP}\gamma\text{S}$ binding assay with a low concentration of guanine nucleotides (GDP + GTP), then this result suggests that the estimate of the $K_a$ of the most efficacious agonist in the $[^{35}\text{S}]\text{GTP}\gamma\text{S}$ assay would be accurate. This information could then be used to assign an appropriate $K_a$ value for the most efficacious agonist in the intact cell assay.

Our inability to estimate the $K_a$ value of oxotremorine-M in the phosphoinositide assay on CHO cells expressing the $M_3$ muscarinic receptor illustrates the problem of estimating $K_a$ for the most efficacious agonist in a series. Given the colossal ratio of $K_a$/$K_{E\text{obs}}$ that is required for agonist A to elicit a near maximal formation of $D_{R^*}\text{GX}$ in the simulation shown in Fig. 3, it seems likely that highly efficacious agonists with more reasonable (i.e., smaller) $K_a$/$K_{E\text{obs}}$ ratios would not cause substantial receptor activation in the presence of the normally high concentration of GTP in the cytosol. Under this condition, the $K_a$ would be approximately equal to $K_{E\text{obs}}$. Strange (2008) has also suggested that the $K_a$ value of an agonist at a G protein-coupled receptor is probably approximately equivalent to $K_{E\text{obs}}$ because of the high concentration of cytosolic GTP. Nonetheless, our demonstration that it is

**TABLE 8**

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Log $EC_{50}$</th>
<th>$E_{max}$</th>
<th>Log $RA_a$</th>
<th>Log $K_{obs}$</th>
<th>Relative Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxotremorine-M</td>
<td>$-6.45$</td>
<td>0.93</td>
<td>2.11</td>
<td>5.32</td>
<td>1.00</td>
</tr>
<tr>
<td>Oxotremorine</td>
<td>$-6.36$</td>
<td>0.61</td>
<td>1.84</td>
<td>5.95</td>
<td>0.13</td>
</tr>
<tr>
<td>Carbachol</td>
<td>$-5.93$</td>
<td>0.80</td>
<td>1.52</td>
<td>5.23</td>
<td>0.32</td>
</tr>
<tr>
<td>Arecoline</td>
<td>$-5.93$</td>
<td>0.68</td>
<td>1.44</td>
<td>5.44</td>
<td>0.17</td>
</tr>
<tr>
<td>S-Aceclidine</td>
<td>$-5.73$</td>
<td>0.60</td>
<td>1.19</td>
<td>5.33</td>
<td>0.12</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>$-5.64$</td>
<td>0.29</td>
<td>0.78</td>
<td>5.49</td>
<td>0.031</td>
</tr>
<tr>
<td>R-Aceclidine</td>
<td>$-5.16$</td>
<td>0.37</td>
<td>0.42</td>
<td>4.96</td>
<td>0.047</td>
</tr>
<tr>
<td>Bethanechol</td>
<td>$-4.77$</td>
<td>0.78</td>
<td>0.35</td>
<td>4.12</td>
<td>0.27</td>
</tr>
<tr>
<td>McN-A-343</td>
<td>$-5.23$</td>
<td>0.12</td>
<td>0.00</td>
<td>5.17</td>
<td>0.010</td>
</tr>
</tbody>
</table>

$^a$ Expressed relative to $M_{sys}$

$^b$ Expressed relative to that of McN-A-343.

$^c$ Expressed relative to that of oxotremorine-M.
only possible to estimate a range of \( K_a \) values for the most efficacious agonist in a series indicates the uncertainty in assuming that \( K_a \) is equivalent to \( K_{obs} \). We have noted that the functional estimates of the \( K_{obs} \) values of efficacious muscarinic agonists for \( M_3 \) and \( M_4 \) receptors expressed in CHO cells and the mouse ileum, respectively, are unusually high, suggesting a substantial deviation of \( K_{obs} \) from \( K_a \) (Tran et al., 2009).

The observed affinity and efficacy of an agonist-receptor complex can change, depending on the concentration of GTP and how the G protein interacts with the receptor (Ehlert and Rathbun, 1990; Ehlert, 2000). When a given agonist-receptor complex is compared across systems, a reduction in the concentration of GTP has the effect of reducing agonist efficacy, because the maximal amount of DR*\( \text{a} \)GX formed is less. When an agonist is compared with other agonists in a series, however, reducing the concentration of GTP has the effect of increasing the efficacy of agonists relative to the most efficacious agonist. In addition, a decrease in GTP causes the efficacy of the most efficacious agonist to achieve, or to come closer to achieving, the maximal level of receptor activation for the system. A plot of relative efficacy against the ratio of \( K_a/K_s \) illustrates this relationship for the theoretical examples shown in Figs. 3 and 5 (Fig. 8a). Even though agonists A to E have the same microscopic affinity constants for the active \( (K_a) \) and inactive \( (K_s) \) states of the receptors in the two simulations, more of the agonists exhibit maximal relative efficacy for the system when the concentration of GTP is low. Figure 8b shows the corresponding plot for the experimental data shown in Fig. 7, a and b.

To summarize, we have developed a method of analysis to estimate the \( K_a \) value of any agonist, full or partial, having an efficacy less than one-third that of the most efficacious agonist in a series. The analysis depends on having accurate estimates of the \( K_{obs} \) values of full agonists, which can be determined using the method of partial receptor inactivation. The analysis provides accurate estimates of \( K_a \) even if \( K_{obs} > K_a \). This condition can occur with a low concentration of GTP in assays on cellular homogenate, and, perhaps, in some intact cell preparations and tissues. Finally, we also show how to estimate the \( K_{obs} \) and relative efficacies of partial agonists from their EC\( 50 \) and \( E_{max} \) values when the Hill slopes of their concentration-response curves are equal to one.

### Appendix

**Simulation of the DR*\( \text{a} \)GX Complex.** We used the model described in Fig. 1 to simulate the amount of agonist \( (D) \) bound in the form of an active quaternary complex \((\text{DR}^*_a\text{GX})\) consisting of the active state of the receptor \((R^*_a)\), the G protein \((G)\), and guanine nucleotide \((X)\). The equation describing the amount of \( \text{DR}^*_a\text{GX} \) as a function of the agonist concentration is as follows:

\[
\text{DR}^*_a\text{GX} = \frac{1}{1 + \frac{[D]R_T}{K_{DR}}} \times \frac{K_R K_s}{K_a [K_a] + K_{DR}X}
\]

in which \( R_T \) denotes the total amount of receptors. The affinity constants with lettered subscripts refer to the properties of the receptor states, and these are defined below by eqs. 44 to 50. The derivation of eq. 30 has been described previously (Ehlert and Rathbun, 1990; Ehlert, 2000). \( K_{DR}X \) is given by

\[
K_{DR}X = 1 + [D][K_1 + G]K_2 + [D][GaK_1K_2 + [X]G[K_2K_3 \times [X][Ga][\gamma K_1K_2K_3]
\]

\[
G = \frac{B + \sqrt{B^2 + 4AC}}{2A}
\]

\[
A = 1 + [X][K_3]
\]

\[
B = r - 1 - AK_G
\]

\[
C = r K_G
\]

\[
K_G = K_r^2 + [D][aK_1K_2 + [X]bK_2K_3 + D[X][a][\gamma K_3K_2K_3]
\]

\[
r = \frac{G_T}{R_T}
\]

In these equations, \( G_T \) and \( G \) denote the total and free concentrations of G protein. The cooperativity constants and microscopic constants for the receptor complexes are defined in Fig. 1a. As described previously (Ehlert, 2000, 2008), these are defined at the level of receptor states by the following equations:

\[
K_1 = \frac{K_a + K_b}{1 + K_c}
\]

\[
K_2 = \frac{K_a + K_b}{1 + K_c}
\]

Fig. 8. Relationship between relative efficacy and the selectivity of agonists for the active state of the receptor. a, relative efficacy is plotted against \( K_a/K_s \) for the data shown in Figs. 3 (GTP = 1.0 mM) and 5 (GTP = 1.8 \( \mu \)M), and b, relative efficacy is plotted against log RA/RI, for the data in Fig. 7, a and b.
we begin by expressing

\[ K_s = K_d \]

\[ \alpha = \frac{(K_rK_e + K_rK_eK_m)(1 + K_s)}{(K_r^2 + K_r^2K_m)(K_r + K_rK_m)} \]

\[ \beta = \frac{K_rK_s + K_rK_eK_m}{(K_r + K_rK_m)} \]

\[ \gamma = \frac{(K_rK_rK_e + K_rK_eK_m)(1 + K_s)}{(K_r^2 + K_r^2K_m)(K_r + K_rK_m)} \]

The fundamental affinity constants for the receptor states are

\[ K_s = \frac{[DR_s]}{[D][R_s]} \]

\[ K_r = \frac{[DR_s^a]}{[D][R_s^a]} \]

\[ K_r = \frac{[R_r][R,G]}{[R_s][G]} \]

\[ K_r^a = \frac{[R_r^a][G]}{[R_r^a][G]} \]

\[ K_r^a = \frac{[R_r^aGX]}{[R_r^a][X]} \]

\[ K_r^a = \frac{[R_r^a]}{[R_r^a]} \]

Solving the limit of the operational model (eq. 18) as \( D \) approaches infinity when \( m = 1 \):

\[ E_{max} = \lim_{D \to \infty} \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \]

Solving this limit yields

\[ E_{max} = \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \]

The EC_{50} value can be solved from the following relationship:

\[ 0.5 \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} = \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \frac{EC_{50}K_{obs}}{E_{max}} \]

The left side of the equation represents the \( E_{max} \) multiplied by 0.5, with the \( E_{max} \) value defined by eq. 53. The right side of the equation represents the operational model with the agonist concentration replaced with by EC_{50}. This equation communicates the idea that the response is half-maximal when the drug concentration equals the EC_{50}. Simplification yields

\[ EC_{50} = \frac{1}{K_{obs}(\tau + 1)} \]

Having expressions for \( E_{max} \) and \( EC_{50} \) enables the proof of the equations for \( K_{obs} \) and relative efficacy (eqs. 28 and 29, respectively) described under Results. \( K_{obs} \) can be estimated from the expression:

\[ \frac{1}{K_{obs}(\tau + 1)} \left( 1 - \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \right) \]

The left side of this equation was derived from the right side by substituting in eqs. 53 and 55 for \( E_{max} \) and \( EC_{50} \), respectively. Simplification yields eq. 28 under Results.

The efficacy of one agonist (\( \epsilon \)), expressed relative to that of another (\( \epsilon' \)), can be estimated from the equation

\[ \frac{M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \left( \frac{M_{sys} - M_{sys}}{1 + \left( \frac{1}{\tau} \right)} \right) = \frac{E_{max}(M_{sys} - E_{max})}{E_{max}(M_{sys} - E_{max})} \]

The left side of this equation was derived from the right side by substituting in eq. 53 for \( E_{max} \). The parameters of the agonist to which the efficacy of the other agonist is normalized are indicated with '. Simplification yields

\[ \frac{\tau}{\tau'} = \frac{E_{max}(M_{sys} - E_{max})}{E_{max}(M_{sys} - E_{max})} \]
Substituting in eq. 19 for $\tau$ yields

$$\frac{\varepsilon R_T}{K_E} = \frac{E_{\text{max}}(M_{\text{sys}} - E_{\text{max}'})}{E_{\text{max}'}(M_{\text{sys}} - E_{\text{max}})}$$

Simplification yields eq. 29 under Results.

Authorship Contributions

**Participated in research design:** Ehlert, Griffin, and Suga.

**Conducted experiments:** Ehlert, Griffin, and Suga.

**Performed data analysis:** Ehlert, Griffin, and Suga.

**Wrote or contributed to the writing of the manuscript:** Ehlert.

References


Ehlert FJ and Rathbun BE (1990) Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations. *Mol Pharmacol* 36:148–158.


Address correspondence to: Dr. Frederick J. Ehlert, Department of Pharmacology, University of California, Irvine, Irvine, CA. E-mail: fjehlert@uci.edu